Reproductive Medicine Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou Guangdong 510080, China; Guangdong Provincial Key Laboratory of Reproductive Medicine, Guangzhou Guangdong 510080, China.
Reproductive Medicine Center, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou Guangdong 510080, China; Guangdong Provincial Key Laboratory of Reproductive Medicine, Guangzhou Guangdong 510080, China.
Reprod Biomed Online. 2022 Aug;45(2):374-383. doi: 10.1016/j.rbmo.2022.03.001. Epub 2022 Mar 5.
Do patients with low ovarian reserve, as defined by the patient-oriented strategies encompassing individualized oocyte number (POSEIDON) criteria, have low euploid blastocyst rates?
Retrospective study of 548 IVF cycles of patients with unexplained recurrent miscarriage who underwent preimplantation genetic test for aneuploidy (PGT-A). Euploid blastocyst rates were analysed to compare patients from POSEIDON groups 3 and 4 (serum anti-Müllerian hormone [AMH] levels <1.2 ng/ml) with those who have normal ovarian reserve (AMH levels ≥1.2 ng/ml) before and after using propensity score matching to match selected variables, such as female age, body mass index, the number of clinical miscarriages, ovarian stimulation protocols and PGT-A analysis platforms. Cycles of patients from POSEIDON groups 3 and 4 were then divided into four groups according to median and quartiles of serum AMH levels: <0.668 ng/ml, 0.668-0.890 ng/ml, >0.890-1.070 ng/ml and >1.070-<1.20 ng/ml. The euploid blastocyst rates were compared across these four groups.
After using propensity score matching, no difference was found in euploid blastocyst rates between patients from POSEIDON groups 3 and 4 and those with normal ovarian reserve. Among cycles of patients from POSEIDON groups 3 and 4, no difference was found in euploid blastocyst rates between the different AMH levels.
The decline in ovarian reserve in patients from POSEIDON groups 3 and 4 was not related to low euploid blastocyst rates. Serum AMH levels do not seem to be a predictor of euploid blastocyst rates in such patients.
根据以患者为导向的个体化卵母细胞数策略（POSEIDON）标准定义的卵巢储备低的患者，其囊胚的整倍体率是否较低？
对 548 个不明原因复发性流产患者的 IVF 周期进行回顾性研究，这些患者接受了植入前遗传学检测以排除非整倍体（PGT-A）。分析整倍体囊胚率，以比较 POSEIDON 组 3 和 4（血清抗苗勒管激素[AMH]水平<1.2ng/ml）的患者与卵巢储备正常（AMH 水平≥1.2ng/ml）的患者，方法是使用倾向评分匹配来匹配选定的变量，如女性年龄、体重指数、临床流产次数、卵巢刺激方案和 PGT-A 分析平台。然后根据血清 AMH 水平的中位数和四分位数将 POSEIDON 组 3 和 4 的周期分为四组：<0.668ng/ml、0.668-0.890ng/ml、>0.890-1.070ng/ml 和>1.070-<1.20ng/ml。比较这四组的整倍体囊胚率。
使用倾向评分匹配后，POSEIDON 组 3 和 4 的患者与卵巢储备正常的患者之间的整倍体囊胚率没有差异。在 POSEIDON 组 3 和 4 的周期中，不同 AMH 水平之间的整倍体囊胚率没有差异。
POSEIDON 组 3 和 4 患者的卵巢储备下降与低整倍体囊胚率无关。血清 AMH 水平似乎不是这些患者整倍体囊胚率的预测因素。
